One additional point for the thread: there's an interesting relationship between hsCRP and statin therapy. The JUPITER trial showed that rosuvastatin reduced cardiovascular events specifically in people with elevated hsCRP (>2.0) even if their LDL was normal. So if you have persistent hsCRP elevation despite weight loss, a statin may provide additional anti-inflammatory cardiovascular protection beyond its cholesterol-lowering effects.
This is an evolving area of cardiology — the intersection of inflammation, lipids, and metabolic health. We're moving beyond "just lower LDL" toward a more comprehensive risk model.